Homer1 polymorphism in patients with Parkinson’s disease and psychosis
Objective: To explore the association of psychosis in Parkinson’s disease with polymorphisms of HOMER1, a gene whose product (Homer1) is responsible for modulating the metabotropic…Attitudes of Care Partners Toward Medications for Parkinson’s Disease Psychosis
Objective: To explore attitudes regarding use of medications among care partners of individuals with Parkinson’s disease psychosis. Background: Parkinson’s disease (PD) psychosis is a highly…Mental Health Matters Too – Integration of physical and mental health in a multidisciplinary Parkinson’s Clinic
Objective: The overall aim of the project was to demonstrate that people with Parkinson’s disease benefit from good mental health care when mental health services…All-cause mortality in pimavanserin and atypical antipsychotic users with Parkinson’s disease in Medicare
Objective: To assess all-cause mortality in Medicare beneficiaries with Parkinson’s disease (PD) receiving pimavanserin or atypical antipsychotics (AAs). Background: In PD patients, the lifetime prevalence…A Systematic Review of the Psychometric Properties of Psychosis Rating Scales in Neurodegenerative Conditions
Objective: To provide an overview of psychosis rating scales validated in specific neurodegenerative disease populations and compare psychometric characteristics of the validated psychosis scales. Background:…Developing A Novel Disease-Specific Psychosis Severity Scale in Parkinson’s disease (Psy-PD): A Pilot Study
Objective: To develop and assess the psychometrics of a disease-specific psychosis severity rating scale (Psy-PD) for a one-stop assessment of change in psychotic symptoms in…Prospective investigation of the frequency of tardive syndromes in outpatients attending two specialist psychiatry hospitals in Lagos, Nigeria
Objective: To determine the frequency and profile of TS in persons on antipsychotics attending tertiary psychiatry hospitals. Background: The term tardive syndrome (TS) encompasses the…Incidence and survival of psychosis in patients with Parkinson’s Disease (1991-2010)
Objective: To determine the incidence of psychosis in patients with Parkinson's disease (PD) and to investigate the survival after a psychosis diagnosis among an incident…A life-threatening case of Anti-IgLON5 disease
Objective: To present a case of anti-IgLON5 disease with life-threatening respiratory complications. Background: Anti-IgLON5 disease is a little known CNS disorder characterized by non-REM and…The mGlu2/3 orthosteric antagonist LY-341,495 abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset
Objective: We seek to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 13
- Next Page »